Document is current
Any future updates will be listed below
-
Authors
Oertel, Wolfgang H. https://orcid.org/0000-0002-7582-8166
Henrich, Martin T. https://orcid.org/0000-0001-8295-4884
Bergquist, Filip https://orcid.org/0000-0002-3437-0267
Janzen, Annette https://orcid.org/0000-0001-8907-5831
Geibl, Fanni F. https://orcid.org/0000-0002-5480-0463
Strupp, Michael https://orcid.org/0000-0002-9544-2279
-
Funding
Funding for this research was provided by:
ParkinsonFonds Deutschland
Philipps-Universität Marburg
- License Information
-
More Information
Article History
Received: 26 February 2025
Revised: 29 May 2025
Accepted: 2 June 2025
First Online: 17 June 2025
Declarations
:
: This single case observational study has been conducted with the drug TanganilR. This drug contains the racemate acetyl-DL-leucine, i.e., to equal parts the bio-inactive substance acetyl-D-leucine and the bioactive enantiomer acetyl-L-leucine. This drug is produced by the company Pierre Fabre, Medicaments, France and approved for the indication vertigo in France. The company Pierre Fabre was not aware of our observational study as none of the authors had any contact during and after the conduct of the study with the company. Wolfgang Oertel (WO) and Michael Strupp (MS) are members of the scientific advisory board of the company IntraBio. WO holds stock options of the company IntraBio, whereas MS is an investor and shareholder of the company Intrabio. In addition, we declare that neither the company Pierre Fabre nor the company IntraBio have supported the conduct of the case report submitted with this article by any means. Wolfgang H. Oertel also acts as a consultant for the company MODAG. He holds stock options with MODAG unrelated to this work. The institution of W.H.O., not W.H.O personally received/s scientific grants from the ParkinsonFonds Deutschland related to the manuscript and from the German Research Foundation, Stichting Parkinson-Fonds, The Netherlands and the Michael J Fox Foundation, USA, all unrelated to the manuscript. Martin T. Henrich has no conflict of interest to declare. Filip Bergquist has no conflict of interest to declare. Annette Janzen has no conflict of interest to declare. Fanni F. Geibl has no conflict of interest to declare. Michael Strupp is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He acts as a consultant for Abbott, AurisMedical, Bulbitec, Heel, Sensorion and Vertify. The institution of M.S., not M.S. personally received/s support for clinical studies from Decibel, U.S.A., Cure within Reach, U.S.A. and Heel, Germany.
: Supplementary Material for ethical considerations.
